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Abstract
　　Despite the high incidence of breast cancer and reports that many affected patients experience 
insomnia, few studies have addressed the incidence of insomnia among women who underwent breast 
cancer screening and biopsy.　Accordingly, this study aimed to assess the prevalence of insomnia 
among women who have undergone breast cancer screening and biopsy and current breast cancer 
patients and identify correlations among insomnia, psychological distress, and quality of life in these 
populations.　The participants were 193 women who visited the breast disease specialty clinic in 
Nagano, Japan.　After stratifying the participants into breast cancer screening (n＝102), breast biopsy (n
＝25), and breast cancer patient (n＝66) groups.
　　Among all groups, 52-57% of the participants experienced insomnia (p＝0.886).　No significant 
differences in the mean HADS scores for anxiety (p＝0.959) and depression (p＝0.755) were observed 
among the three groups.　Among breast cancer patients, several EORTC QLQ-C-30 items correlated 
with insomnia, whereas fewer such correlations were observed among participants undergoing breast 
cancer screening and breast biopsy.　These findings suggest that women undergoing breast screening or 
biopsy experience similar psychological distress and insomnia as that reported by breast cancer patients.　
However, the quality of life of breast cancer patients was more strongly affected by insomnia, suggest-
ing that this is a chronic factor in this population.
Introduction
　　Breast cancer is the most common cancer 
among women worldwide.　In Japan, approxi-
mately 89,400 women were newly diagnosed with 
this disease in 20151).　Although patients recently 
diagnosed with early-stage breast cancer have a 
5-year survival rate above 90%, patients report 
insomnia as the most frequent and severe cluster 
of symptoms, followed by pain, fatigue, and 
depression2-4).
　　Psychological stress is known to disturb 
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sleep in both real-life and clinical situations5,6), 
and insomnia is a common psychophysiological 
response to situational stress, anxiety, and fear.　
Over time, chronic insomnia has various detri-
mental health effects, including altered metabolic 
and endocrine function7) and hypothalamic-pitu-
itary-adrenal (HPA) axis activity8,9).　Insomnia 
also reduces the function of biological repair and 
immune mechanisms10) and increases the risks of 
hypertension11), depression12-14), and heart dis-
ease15).
　　According to a review by Buysse insomnia 
affects approximately 10-20% of people in the 
general population16).　In Japan, many women 
report experiencing insomnia caused by stressors 
such as nursing home care, working, and parent-
ing (i.e., 24-hour lifestyle situations)17,18).　
Although several studies report that 21-26% of 
adult women (age:＞20 years) have insomnia19,20), 
studies of cancer patients report rates of 30-75%, 
or twice as high as the rates in the general popu-
lation21).
　　In addition to cancer patients, Kitano et al.22) 
and Nelson et al.23) reported that women undergo-
ing breast cancer screening and Schnur et al.24) 
reported that breast biopsy have very high levels 
of psychological stress.　In brief, many women 
are likely to experience insomnia, defined as dif-
ficulty initiating or maintaining sleep, with under-
lying symptoms including difficulty falling 
asleep, difficulty staying asleep, early morning 
awakening, or non-restorative sleep during the 
past week.　However, few studies have evaluated 
the prevalence of insomnia in this population.　
The present study, therefore, is the first to com-
pare the prevalence of insomnia among breast 
cancer patients and women undergoing breast 
cancer screening and biopsy.　With this compari-
son, the study aims to assess not only the preva-
lence of insomnia, but also to identify correlations 
among insomnia, psychological distress, and the 




　　This cross-sectional study was conducted 
from February 2016 through March 2017.
Participants
　　Participants were recruited from the breast 
cancer specialty clinic in Nagano, Japan.　The 
inclusion criteria were an age of ≥20 years and 
the ability to read and respond in writing to Japa-
nese-language questionnaires.　The exclusion 
criteria were a diagnosis of benign breast disease 
and non-breast examination.　The same criteria 
were applied to women with and without a breast 
cancer diagnosis.
　　A total of 528 envelopes were distributed to 
potential study participants.　Of these, 292 were 
returned to the researcher for a response rate of 
55.3%.　After applying the inclusion and exclu-
sion criteria, 99 responses were excluded to yield 
a total of 193 completed data sets.　The partici-
pants were subsequently divided into three groups 
depending on the purpose of their visit to the 
clinic: breast cancer patients (n＝66, 34.2%), 
breast cancer screening (n＝102, 52.8%), and pre-
cise breast cancer biopsy (n＝25, 13.0%).
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Procedure
　　Survey participants were recruited via adver-
tising posters placed on the wall of the clinic 
waiting room.　The envelopes provided to poten-
tial participants included a paper copy of the 
survey outline, set of questionnaires, prepaid 
envelope, felt-tip pen for filling out the question-
naire, and reward (approximately 150 Japanese 
yen worth of bath salts).　The participants were 
allowed to complete the survey in the waiting 
room or at home and were requested to mail com-
pleted questionnaires directly to the researcher.　
Only the attending physician, nurse,  and 
researcher were aware of study participation.　
The return of a questionnaire to the researcher 
was considered to indicate consent to participate 
in the study.　The study was approved by the 
Ethical Committee of Saku University (approval 
no.: 15-0003-04).
Measures
　　The survey questionnaire comprised demo-
graphic, psychosocial, and clinical questions.　
Eligible participants were invited to complete the 
Hospital Anxiety and Depression Scale (HADS), 
Japanese version25), the Japanese-language Euro-
pean Organization for Research and Treatment of 
Cancer QOL questionnaire (EORTC QLQ-C30) 
ver. 3.0, and questions to determine demographic 
data, the presence of insomnia, and psychosocial 
and clinical factors, such as age, employment, 
marital status, children, reason for visit, survival 
years, and social support.
　　Many studies have been conducted to evalu-
ate anxiety and depression in cancer patients22,26,27).　
The HADS is a major tool used to detect anxiety 
and depression.　It was developed in England to 
measure anxiety and depression levels in patients 
unaffected by physical symptoms at general out-
patient clinics28).　The HADS consists of seven 
items related to anxiety and seven related to 
depression.　Total scores of 0-7, 8-10, and ≥11 
reflect ‘non-cases’, ‘doubtful cases’, and ‘defi-
nite cases’, respectively.　Many studies have 
tested, summarized, and validated the HADS29), 
and the Japanese version25) was validated in 
female university students and laborers30) in a gas-
trointestinal outpatient clinic31).
　　Insomnia also affects the physical, mental, 
and social functioning aspects of the QOL, which 
is an important measure in cancer patients.　To 
address the QOL, we used the Japanese-language 
EORTC QLQ-C30 ver. 3.0, a major health-related 
QOL assessment designed for cancer patients.　
The EORTC QLQ-C30 was developed by the 
European Organisation for Research and Treat-
ment of Cancer and comprises 30 items32), includ-
ing a global health status/QOL scale, five 
functional scales (physical, role, emotional, cog-
nitive, and social), three symptom scales (fatigue, 
nausea and vomiting, and pain), and six single 
scales (dyspnea, appetite loss, insomnia, constipa-
tion, diarrhea, and financial difficulties).　This 
tool has been validated in many studies33), includ-
ing studies of the QOL of breast cancer patients27,34,35).　
High scores on the functional scales indicate good 
health, while high scores on the symptom scales 
indicate health problems.
Analyses
　　The three groups of participants were com-
pared in terms of demographic, psychosocial, the 
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prevalence of insomnia, and clinical factors using 
a chi-squared test.　The mean group HADS and 
EORTC QLQ-C30 scores in the groups were 
compared using a one-way analysis of variance.　
Multiple post hoc comparisons were corrected 
using Dunnett’s method.　Correlations of the 
presence of insomnia with HADS subscale scores 
and EORTC QLQ C-30 item scores were deter-
mined using Spearman’s correlation coefficient 
analyses.　Differences were considered to be sig-
nificant at a level of 5%.　The analyses were per-
formed using SPSS, version 25.0 (IBM Japan, 
Tokyo, Japan).
Results
Socio-demographic and clinical characteristics
　　Table 1 presents the patients’ socio-demora-
phic and clinical characteristics stratified by the 
purpose of the visit to the clinic.　The study par-
ticipants had a mean (±standard deviation) age 
of 51.4±10.8 years and a median (range) age of 
50.0 (20-77) years.　Although patients in the 
breast screening group were significantly younger 
than those in other groups (p＜0.001), the groups 
did not differ significantly in terms of employ-
ment, marital status, children younger than 12 
years, and social support.　Among breast cancer 
patients, the mean survival time was 6.25±5.0 





N 102 25 66
N ％ N ％ N ％ p
Age (mean±SD) 48.9±10.3 49.2±10.9 56.0±10.0 ＜0.001**
　Range 27-75 20-75 34-77
　Younger than 35 years  9  8.8  2  8.0  1  1.5
　Older than 65 years 10  9.8  1  4.0 16 24.2
Employment
　Employed 80 78.4 19 76.0 44 66.7 0.229
Marital status
　Married 81 79.4 21 84.0 55 83.3 0.197
　Divorce/bereavement 12 11.8  0 　 0  8 12.1
　Unmarried  9  8.8  4 16.0  3  4.5
Has children younger than 12years 26 25.5  6 24.0  7 10.6 0.056
Has children older than 12years 35 34.3 12 48.0 33 50.0 0.102
Social support
　Husband 72 70.6 15 60.0 39 59.1 0.260
　Parent 39 38.2 11 44.0 23 34.8 0.718
　Child 60 58.8 15 60.0 39 59.1 0.994
　Friend 51 50.0  8 32.0 29 43.9 0.255
Notes: SD＝ standard deviation　** p＜0.01
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years, and two patients (3.3%) survived for less 
than 1 year.
Insomnia
　　Fifty-eight (56.9%), 13 (52.0%), and 38 
(57.6%) of patients in the breast cancer screening, 
biopsy, and patient groups, respectively, reported 
insomnia, including difficulty falling asleep, diffi-
culty returning to sleep after awakening, or awak-
ening too early with an inability to return to sleep.　
In other words, more than half of all participants 
in each group experienced insomnia, and no sig-
nificant differences were observed among the 
groups (p＝0.886).
　　Breast cancer patients had the highest mean 
insomnia score which is one of the item of 
EORTC QLQ C-30 item score of 19.7±26.8.　
The insomnia raw score was determined by how 
often insomnia occurred, as well as the response 
to ‘Have you had trouble sleeping?’, which had 
three possible answers: 1.　Not at all, 2.　A little, 
3.　Quite a bit, and 4.　Very much.　Of the 
screening, biopsy, and patient groups, 7.8%, 
4.0%, and 10.6% respectively reported responses 
3 and 4, while 38.2%, 44.0%, and 43.9% respec-
tively reported responses of 2-4.
HADS
　　The three groups did not differ significantly 
in terms of the mean HADS score (anxiety: p＝
0.959, depression: p＝0.755).　Using a cut-off 
point of 7/8, 19-22% of patients in the three 
groups were classified as doubtful and definite
cases (Table 2).　Although there were no signifi-
cant differences among the groups for percentage 
of doubtful and definite cases of HADS score 
(anxiety: p＝0.895, depression: p＝0.902).
EORTC QLQ C-30
　　Table 3 presents the mean EORTC QLQ 
C-30 scores.　Surprisingly, breast cancer patients 
had the highest global health status score (70.3±
21.6), although there were no significant differ-
ences among the groups (p＝0.164).　Significant 
inter-group differences were observed for the 
physical functioning (p＝0.007), social function-
ing (p＝0.025), diarrhea (p＝0.007), and financial 
difficulties scale scores (p＝0.003).　The biopsy 
group had the highest diarrhea score (12.0±25.2), 
and the breast cancer patients group had the high-
est financial difficulties score (22.7±31.6).
Table 2　Comparison and distribution of mean HADS scores
0-7 ≥ 8
F-test χ 2 test
Mean SD N ％ N ％
HADS-anxiety Screening 5.3±3.4 79 77.5 23 22.5 p＝0.959 p＝0.895
Biopsy 5.2±3.6 20 80.0 5 20.0
Breast cancer 5.1±2.8 53 80.3 13 19.7
HADS-depression Screening 4.7±3.4 81 79.4 21 20.6 p＝0.755 p＝0.902
Biopsy 5.2± 4.2 19 72.7 6 24.0
Breast cancer 4.6±3.1 53 82.0 13 19.7
Notes: HADS＝ Hospital Anxiety and Depression Scale; SD＝ standars deviation
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Correlation insomnia and HADS, EORTC QLQ 
C-30
　　Table 4 presents the results of a correlation 
analysis of insomnia, the HADS subscale scores, 
and the EORTC QLQ C-30 item scores.　Only 
weak correlations were observed between the 
HADS subscale score and insomnia (r＝0.232-
0.263) in the screening group, and insomnia cor-
related with only depression among breast cancer 
patients (r＝0.506).　Furthermore, only two 
EORTC QLQ C-30 items correlated with insom-
nia in the screening group, while three and seven 
items correlated with insomnia in the biopsy and 
breast cancer patient groups.
Discussion
　　In this study, we observed an approximately 
50% prevalence of  insomnia,  which was 
attributed to several types of sleep disturbance.　
Although we observed the highest mean EORTC 
QLQ C-30 insomnia raw score among breast 
cancer patients in our study, this parameter did 
not differ significantly among the groups.　This 
prevalence of insomnia was approximately two- 
to three-fold higher than the rates reported by 
previous studies conducted among Japanese 
women (14.4-26%)19,20,36) but was consistent with 
previous studies in which the prevalence of 
insomnia was approximately two- to three-fold 
higher among cancer patients relative to the gen-
eral population21,37).　Despite these observations, 
no previous study has used the same tools to eval-
Table 3　Comparison of mean EORTC QLQ C-30 item scores among patients in the screening, biopsy, and 
breast cancer groups
Screening Biopsy Breast cancer
pN＝102 N＝25 N＝66
Mean　SD Mean　SD Mean　SD
Global health status/QOL 64.4± 22.1 62.3± 20.6 70.3± 21.6 0.164
Physical functioning 92.5± 9.7 92.3± 9.4 87.3± 12.7 0.007 **
Role functioning 93.3± 15.2 92.0± 15.3 92.2± 14.7 0.863
Emotional functioning 77.5± 18.8 75.7± 16.3 80.2± 17.3 0.490
Cognitive functioning 75.8± 20.0 78.0± 21.4 74.5± 16.1 0.727
Social functioning 91.2± 17.7 80.0± 28.5 85.6± 19.6 0.025 *
Fatigue 30.3± 20.0 36.4± 21.2 31.1± 20.0 0.391
Nausea and vomiting 4.1± 11.8 2.0± 5.5 0.8± 3.5 0.065
Pain 19.4± 23.3 20.0± 21.5 21.7± 21.1 0.811
Dyspnea 7.5± 17.6 9.3± 15.3 9.6± 16.3 0.613
Insomnia 16.3± 24.3 16.00± 19.5 19.7± 26.8 0.656
Appetite loss 7.8± 16.4 9.3± 15.3 7.1± 13.7 0.820
Constipation 15.4± 24.2 21.3± 31.7 16.7± 23.6 0.567
Diarrhea 7.2± 17.9 12.0± 25.2 1.0± 5.8 0.007 **
Financial difficulties 9.5± 19.6 20.0± 28.9 22.7± 31.6 0.003 **
Notes: EORTC QLQ C-30＝ European Oganization for Research and Treatment of Cancer Quality of Life Ques-
tionnaire; SD＝standard deviation; QOL＝quality of life　* p＜0.05; ** p＜0.01
7Correlations among insomnia, psychological distress, and quality of life in a population of ambulatory 
women undergoing breast cancer screening, biopsy, and diagnosis
uate the prevalence of insomnia among patients 
with breast cancer, as well as those undergoing 
breast cancer screening and biopsy.
　　On the other hand, the present study 
observed a prevalence of anxiety or depression of 
19.7% among breast cancer patients, which was 
slightly higher than the rate reported by Akechi et 
al.38) but within the range of 10-25% reported by 
Fann et al.39) regarding the prevalence of depres-
sion among breast cancer patients.
　　Although the correlation between insomnia 
and each item of the EORTC QLQ C-30 was 
weak in the screening group, moderate correlation 
was found between emotional function and social 
function in the biopsy group.　In using the 
EORTC QLQ C-30 for breast cancer patients 
before surgery, Denieffe et al.40) found that 
“fatigue,” “depression,” “pain,” and “sleep dis-
turbance” were inter-related symptom clusters, 
and similar to our research, these clusters were 
weakly correlated with emotional function and 
social function.　In the group of breast cancer 
patients, “insomnia” correlated with “fatigue,” 
“pain,” and “depression;” therefore, it turned out 
that these factors were affecting each other as a 
cluster.　In addition, we acknowledged that 
breast cancer patients were continuously suffering 
from stress, because correlations were found not 
only with regard to physical aspects but also with 
emotional, cognitive, and social functions.
　　Screening and biopsy are temporary events 
and are thus considered acute stressors, whereas 
breast cancer patients may experience chronic 
insomnia due to continuous stress.　This chronic 
nature may affect many QOL items.　However, 
we were not able to clarify whether the similar 
prevalence of insomnia in breast cancer patients 
relative to other groups indicates that women who 
Table 4　Spearman correlations of insomnia with EORTC QLQ C-30 scores
Screening Biopsy Breast cancer
Global health status/QOL －0.306 *
Physical functioning 0.231 *
Role functioning
Emotional functioning －0.459 * －0.456 *
Cognitive functioning －0.393 *
Social functioning －0.505 * －0.331 *




Appetite loss 　0.295 *
Constipation
Diarrhea
Financial difficulties 　0.396 *
HADS-anxiety 0.232 *
HADS-depression 0.263 ** 　 0.506 **
Notes: Data are shown as R values. EORTC QLQ C-30＝ European Oganization for Research and Treatment of 
Cancer Quality of Life Questionnaire; QOL＝ quality of life; HADS＝ Hospital Anxiety and Depression Scale
* p＜0.05; ** p＜0.01
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experience acute insomnia attributable to screen-
ing or biopsy will develop chronic insomnia fol-
lowing a breast cancer diagnosis.　This topic 
should be addressed in future research.
　　This study had some limitations of note.　
The total number of participants may not be suffi-
cient for analyses among the groups, and the 
questionnaires were completed either at the clinic 
or after going home.　Accordingly, some of the 
patients responded to the questionnaire after 
receiving a diagnosis of non-cancer, despite that 
some studies have shown that patients who 
undergo a breast tumor biopsy experience high 
levels of anxiety and depression before receiving 
a diagnosis.　Furthermore, this study did not 
investigate whether the cancer stage, treatment 
type, or menopausal/post-menopausal status 




　　This study was supported by the Japan Soci-
ety for the Promotion of Science Grant-in-Aid for 
Scientific Research (C), Grant Number: JP26463360.
References
 1) Cancer Statistics in Japan (2016). Foundation for 
Promotion of Cancer Research. Retrieved from http://
ganjoho.jp/data/reg_stat/statistics/brochure/2015/
cancer_statistics_2015_date_J.pdf
 2) Ho, S.-Y., Rohan, K. J., Parent, J., Tager, F. A., & 
McKinly, P. S. (2015). A longitudinal study of depres-
sion, fatigue, and sleep disturbances as a symptom 
cluster in women with breast cancer. Journal of Pain 
and Symptom Management, 49, 707-715.
 3) Fiorentino, L., Rissing, M., Liu, L., & Ancoli-Israel, 
S. (2011). The symptom cluster of sleep, fatigue and 
depressive symptoms in breast cancer patients: Sever-
ity of the problem and treatment options. Drug Discov-
ery Today Disease Models, 8, 167-173.
 4) Sarenmalm, E. K., Browall, M., & Gaston-Johans-
son, F. (2014). Symptom burden clusters: A challenge 
for targeted symptom management. A longitudinal 
study examining symptom burden clusters in breast 
cancer. Journal of Pain and Symptom Management, 47, 
731-741.
 5) Budhrani, P. H., Lengacher, C. A., Kip, K., Tof-
thagen, C., & Jim, H. (2015). An integrative review of 
subjective and objective measures of sleep distur-
bances in breast cancer survivors. Clinical Journal of 
Oncology Nursing, 19, 185-191.
 6) Dooyoung, J., Lee, K. M., Kim, W. H., Lee, J. Y., 
Kim, T. Y., Im, S. A., … Harm, B. J. (2016). Longitu-
dinal association of poor sleep quality with chemo-
therapy-induced nausea and vomiting in patients with 
breast cancer. Psychosomatic Medicine, 78, 959-965.
 7) Hirotsu, C., Tufik, S., & Andersen, M. L. (2015). 
Interactions between sleep, stress, and metabolism: 
From physiological to pathological conditions. Sleep 
Science, 8, 143-152.
 8) Burckley, T. M., & Schatzberg, A. F. (2005). On the 
interactions of the hypothalamic-pituitary-adrenal 
(HPA) axis and sleep: Normal HPA axis activity and 
circadian rhythm, exemplary. Journal of Clinical Endo-
crinology & Metabolism, 90, 3106-3114.
 9) Han, K. S., Kim, L., & Shim, I. (2012). Stress and 
sleep disorder. Experimental Neurobiology, 21, 141-
150.
10) Majde, J. A., & Krueger, J. M. (2005). Links 
between the innate immune system and sleep. Journal 
of Allergy and Clinical Immunology, 116, 1188-1198.
11) Thomas, S. J., & Calhoun, D. (2017). Sleep, insom-
nia, and hypertension: Current findings and future 
directions. Journal of the American Society of Hyperten-
sion, 11, 122-129.
12) Nishitani, N., Kawasaki, Y., & Sakakibara, H. 
(2018). Insomnia and depression: Risk factors for 
development of depression in male Japanese workers 
9Correlations among insomnia, psychological distress, and quality of life in a population of ambulatory 
women undergoing breast cancer screening, biopsy, and diagnosis
during 2011-2013. International Journal of Health, 63, 
49-55.
13) Li, L., Wu, C., Gan, Y., Qu, X., & Lu, Z. (2016). 
Insomnia and the risk of depression: A meta-analysis 
of prospective cohort studies. BMC Psychiatry, 16, 375.
14) Fernandez-Mendoza, J., Shea, S., Vgontzas, A. N., 
Calhoun, S. L., Liao, D., & Bixler, E. O. (2015). 
Insomnia and incident depression: Role of objective 
sleep duration and natural history. Journal of Sleep 
Research, 24, 390-398.
15) Javaheri, S., & Redine, S. (2017). Insomnia and risk 
of cardiovascular disease. Chest, 152, 435-444.
16) Buysse, D. J. (2013). Insomnia. Journal of the Ameri-
can Medical Association, 20, 706-716.
17) Tokiya, M., Kaneita, Y., Itani, O., Jike, M., & Ohida, 
T. (2016). Predictors of insomnia onset in adolescents 
in Japan. Sleep Medicine, 38, 37-43.
18) Wyse, C., Carlos, A., Morales, C., Graham, N., Fan, 
Y., Ward, J., … Pell, J. P. (2017). Adverse metabolic 
and mental health outcomes associated with shiftwork 
in a population-based study of 277,168 workers in UK 
biobank. Annals of Medicine, 49, 411-420.
19) Komada, Y., Nomura, T., Kusumi, M., Nakashima, 
K., Okajima, I., Sasai, T., & Inoue, Y. (2011). Correla-
tions among insomnia symptoms, sleep medication 
use and depressive symptoms. Psychiatry and Clinical 
Neurosciences, 65, 20-29.
20) Kim, K., Uchiyama, M., Okawa, M., Liu, Z., & Ogi-
hara, R. (2000). An epidemiological study of insomnia 
among the Japanese general population. Sleep, 23,1-7.
21) Howell, D., Oliver, T. K., Keller-Olaman, S., David-
son, J. R., Garland, S., Samuels, C., …Taylor, C. 
(2014). Sleep disturbance in adults with cancer: A sys-
tematic review of evidence for best practices in assess-
ment and management clinical practice. Annals of 
Oncology, 25, 791-800.
22) Kitano, A., Yamauchi, H., Hosaka, T., Yagata, H., 
Hosokawa, K, Ohde, S., … Tsunoda, H. (2015). Psy-
chological impact of breast cancer screening in Japan. 
International Journal of Clinical Oncology, 20, 1110-
1116.
23) Nelson, H., Pappas, M., Canter, A., Griffin, J., 
Daeges, M., & Humphrey, L. (2016). Harms of breast 
cancer screening: Systematic review to update the 
2009 U.S. preventive services task force recommenda-
tion. Annals of Internal Medicine, 164, 256-267.
24) Schnur, J. B., Montgomery, G. H., Hallquist, M. N., 
Goldfarb, A. B., Silverstein, J. H., Weltz, C. R., … 
Bovbjerg, D. H. (2008). Anticipatory psychological 
distress in women scheduled for diagnostic and cura-
tive breast cancer surgery. International Journal of 
Behavioral Medicine, 15, 21-28.
25) Kitamura, T. (1993). Hospital anxiety and depression 
scale. Archives of psychiatric diagnostics and clinical 
evaluation, 993, 371-372. [Japanese]
26) Hinz, A., Krauss, O., Hauss, J. P., Höckel, M., Kort-
mann, R. D., Stolzenburg, J. U., & Schwarz, R. (2010). 
Anxiety and depression in cancer patients compared 
with the general population. European Journal of 
Cancer Care, 19, 522-529.
27) Schleife, H., Sachtleben, C., Barboza, C. F., Singer, 
S., & Hinz, A. (2014). Anxiety, depression, and quality 
of life in German ambulatory breast cancer patients. 
Breast Cancer, 21, 208-213.
28) Zigmond, A. S., & Snaith, R. P. (1983). The hospital 
anxiety and depression Scale. Acta Psychiatrica Scan-
dinavica, 67, 361-370.
29) Bjelland, B., Dahl, A. A., Haug, T. T., & Neckel-
mann, D. (2002). The validity of the hospital and 
depression scale an updated literature review. Journal 
of Psychosomatic Research, 52, 69-77.
30) Hatta, H., Higashi, A., Yashiro, H., Ozasa, K., 
Hayashi, K., Kiyota, K., … Kawai, K. (1998). A vali-
dation of the hospital anxiety and depression scale. 
Japanese Journal of Psychosomatic Medicine, 38, 309-
315. [Japanese]
31) Higashi, A., Yashiro, H., Kiyota, K., Inokuchi, H., 
Hatta, H., Fujita, K., … Kawai, K. (1996). Validation 
of the hospital anxiety and depression scale in a gas-
tro-intestinal clinic. Japanese Journal of Gastroentero-
logical Surgery, 93, 884-892. [Japanese]
32) Aaronson, N. K., Ahmedzai, S., Bergman, B., 
Bullinger, M., Cull, A., Duez, N. Z., … Takeda, F. 
(1993). The European organization for research and 
treatment of cancer QLQ-C30: A quality-of-life instru-
ment for use in international clinical trials in oncology. 
Journal of the National Cancer Institute, 85, 365-376.
33) Groenvold, M., Klee, M. C., Sprangers, M. A. G., & 
高崎健康福祉大学紀要　第18号　201910
Aaronson, N. K. (1997). Validation of the EORTC 
QLQ-C30 quality of life questionnaire through com-
bined qualitative and quantative assessment of 
patient-observer agreement. Journal of Clinical Epide-
miology, 50, 441-450.
34) Fischer, M. J., Inoue, K., Matsuda, M., Kroep, J. R., 
Nagai, S., Tozuka, K., … Kaptein, A. A. (2017). 
Cross-cultural comparison of breast cancer patients’ 
Quality of Life in the Netherlands and Japan. Breast 
Cancer Research and Treatment, 166, 459-471.
35) Schou, I., Ekeberg, Ø., Ruland, C. M., Sandvik, L., 
& Kåresen, R. (2005). Pessimism as a predictor of 
emotional morbidity one year following breast cancer 
surgery. Psycho-Oncology, 13, 309-320.
36) Doi, Y., Minowa, M., Okawa, M., & Uchitomi, M. 
(2000). Prevalence of sleep disturbance and hypnotic 
medication use in relation to sociodemographic factors 
in general Japanese adult population. Journal of Epide-
miology, 10, 79-86.
37) Liu, L., & Ancoli-Israel, A. (2008). Sleep distur-
bances in cancer. Psychiatric Annals, 38, 627-634.
38) Akechi, T., Okuyama, T., Imoto, S., Yamazaki, S., & 
Uchitomi, Y. (2001). Biomedical and psychosocial 
determinants of psychiatric morbidity among postop-
erative ambulatory breast cancer patients. Breast 
Cancer Research and Treatment, 65, 195-202.
39) Fann, J. R., Thomas-Rich, A. M., Katon, W. J., 
Cowley, D., Pepping, M., McGregor, B. A., & Gralow, 
J. (2008). Major depression after breast cancer: A 
review of epidemiology and treatment. General Hospi-
tal Psychiatry, 30, 112-126.
40) Denieffe, S., Gowman, S., Gooney, M. (2013). 
Symptoms, clusters and quality of life prior to surgery 
for breast cancer. Journal of Clinical Nursing, 23, 2491-
2502.
